Access is our top priority

  • Financial assistance

    Help identifying and evaluating the potential options based on your patient’s insurance plan and eligibility.a

  • Limited Drug Program

    Quick Start Program: For NEW patients who have a recent denial
    or treatment delay.b

    Bridge Program: For EXISTING patients who have a recent denial or treatment delay.b

  • No insurance or underinsured
    for an Alfasigma therapy

    Qualified patients may be provided with access to Alfasigma treatment at no cost under the Patient Assistance Program.

Enroll Your Patients in Interconnect Now

aCertain offers not valid for patients enrolled in Medicare, Medicaid, VA, DoD, Tricare, or other federal or state healthcare programs. For program terms, conditions, and eligibility criteria, click here.

bFor eligible commercial patients.

You are now leaving Interconnect

Any information you provide after you leave this site and enter another site will be subject to the other website’s privacy policy and terms and conditions. Interconnect is not responsible for the use, security, or disclosure of any information you may provide to another site.

Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., has voluntarily withdrawn OCALIVA® (obeticholic acid) from the market for the treatment of primary biliary cholangitis (PBC), effective November 14.

Patients should talk to their healthcare professionals and may also contact Intercept's patient support services (Interconnect at 1-844-622-4278) through December 31, 2025.

Interconnect's website is being temporarily maintained and is no longer fully functional for enrollment purposes due to the withdrawal of OCALIVA.

Healthcare professionals can contact Medical Information at medinfo@interceptpharma.com or 1-844-782-4278. Additionally, patients or healthcare professionals may request Full Prescribing Information or the OCALIVA Medication Guide by contacting medinfo@interceptpharma.com.

For all other inquiries please contact: info@interceptpharma.com